RDEA Ardea Biosciences, Inc. (MM)

LONDON--Biopharmaceutical business AstraZeneca PLC (AZN.LN) said Wednesday that on June 19 it completed its acquisition of San Diego, California-based biotechnology company Ardea Biosciences, Inc. (RDEA).

MAIN FACTS:

-Upon completion of the merger, each outstanding share of Ardea common stock was cancelled and converted into the right to receive 32 dollars, in cash, without interest, and shares of Ardea common stock ceased trading on the NASDAQ Global Select Market.

-AstraZeneca shares closed Tuesday at 2760 pence valuing the company at 34.8 billion pounds.

-Write to Ian Walker at ian.walker@dowjones.com